Related Experiment Video
Updated: Jan 21, 2026
08:24
The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
Published on: August 25, 2023
1.1K
[Outcome studies on SGLT-2 inhibitors]
1Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Medizinische Fakultät, Universität Freiburg, Hugstetter Straße 55, 79106, Freiburg, Deutschland. jochen.seufert@uniklinik-freiburg.de.
Der Internist
|August 4, 2019
Summary
Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors show significant cardiovascular and renal benefits in type 2 diabetes patients. These drugs are recommended for patients with established cardiovascular disease, heart failure, or kidney disease.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors represent a novel class of oral antidiabetic drugs.
- These drugs exert a unique mechanism of action within the kidneys to manage blood glucose levels.
Purpose of the Study:
- To evaluate the cardiovascular (CV) and renal effects of SGLT-2 inhibitors.
- Analysis focused on outcome trials involving patients with type 2 diabetes.
Main Methods:
- Differential analysis and interpretation of results from major SGLT-2 inhibitor outcome trials.
- Key drugs analyzed include empagliflozin, canagliflozin, and dapagliflozin in type 2 diabetes mellitus patients.
Main Results:
- Empagliflozin in EMPA-REG OUTCOME significantly reduced MACE, heart failure hospitalizations, renal endpoints, and mortality.
- Canagliflozin in CANVAS and CREDENCE trials demonstrated significant reductions in MACE, heart failure hospitalizations, and renal endpoints.
- Dapagliflozin in DECLARE-TIMI 58 showed significant reductions in a composite of CV death and heart failure hospitalization.
Conclusions:
- SGLT-2 inhibitor outcome trials collectively demonstrate cardioprotective and nephroprotective benefits.
- These benefits are evident in type 2 diabetes patients with high CV risk.
- Current guidelines recommend SGLT-2 inhibitors as primary partners with metformin for specific patient groups.
Keywords:
Cardiovascular diseasesCardiovascular treatment outcomesDiabetes mellitus, type 2Kidney diseasesRenal treatment outcomesMore Related Videos
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
02:24Predicting Reaction Outcomes
10.3K
Kinetics describes the rate and path by which a reaction occurs. In contrast, thermodynamics deals with state functions and describes the properties, behavior, and components of a system. It is not concerned with the path taken by the process and cannot address the rate at which a reaction occurs. Although it does provide information about what can happen during a reaction process, it does not describe the detailed steps of what appears on an atomic or a molecular level. On the other hand,...
10.3K
01:13Outcomes of Glycolysis
106.8K
Nearly all the energy used by cells comes from the bonds that make up complex organic compounds. These organic compounds are broken down into simpler molecules, such as glucose. As a result, cells extract energy from glucose over many chemical reactions—a process called cellular respiration.
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
106.8K
01:11Guidelines for Writing Outcome
3.7K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.7K
01:23Dipeptidyl Peptidase 4 Inhibitors
608
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
608
01:13meta-Directing Deactivators: –NO2, –CN, –CHO, –CO2R, –COR, –CO2H
6.6K
All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for...
6.6K